New hope for lymphoma patients: drug combo trial launches
NCT ID NCT07208981
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two different drug combinations for people newly diagnosed with marginal zone lymphoma, a slow-growing blood cancer. One group gets a new targeted therapy (orelabrutinib) plus two other drugs, while the other gets standard chemo-immunotherapy. The goal is to see which works better at controlling the disease for longer. About 169 adults aged 18-75 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a maintenance drug keep lymphoma at bay? new trial aims to find out.
- New drug takes aim at Hard-to-Treat blood cancers
- CAR-T therapy Follow-Up study shows no new safety surprises
- New Risk-Adapted drug combo aims to outsmart lymphoma
- New combo therapy aims to shrink lymphoma tumors in untreated patients
- New combo therapy aims to wipe out lymphoma without prior treatment